These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 25998416)

  • 41. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe.
    Gao S; Barber B; Schabert V; Ferrufino C
    Curr Med Res Opin; 2012 Jul; 28(7):1111-8. PubMed ID: 22587480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.
    van de Ven S; Smit VT; Dekker TJ; Nortier JW; Kroep JR
    Cancer Treat Rev; 2011 Oct; 37(6):422-30. PubMed ID: 21177040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities.
    Conlin AK; Seidman AD
    Clin Breast Cancer; 2008 Jun; 8(3):215-23. PubMed ID: 18650151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
    Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
    Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast Cancer: Current Molecular Therapeutic Targets and New Players.
    Nagini S
    Anticancer Agents Med Chem; 2017; 17(2):152-163. PubMed ID: 27137076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
    Cerne JZ; Ferk P; Frkovic-Grazio S; Leskosek B; Gersak K
    Climacteric; 2012 Feb; 15(1):68-74. PubMed ID: 22132797
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.
    Han Y; Wu Y; Xu H; Wang J; Xu B
    Int J Clin Oncol; 2022 Apr; 27(4):707-716. PubMed ID: 35041101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?
    Khasraw M; Brogi E; Seidman AD
    Curr Oncol Rep; 2011 Feb; 13(1):17-25. PubMed ID: 21053108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.